GlassScriptPhysician profile
Stephanie Tafflinger
NPI 1619669900
$3,098.30
in general payments reported to CMS, 2019-2025
22 companies · $1,017 in 2025
The $1,017 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $105 · 2024: $1,976 · 2025: $1,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,292 · Travel and Lodging: $721 · Gift: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,292.42 |
| Travel and Lodging | $720.88 |
| Gift | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,117.31 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Sequel Med Tech, LLC | $382.35 | 2025 | Twiist |
| Novo Nordisk INC | $202.04 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Tandem Diabetes Care, INC. | $189.18 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $169.19 | 2024-2025 | |
| Corcept Therapeutics | $147.56 | 2024-2025 | Korlym |
| Lilly USA, LLC | $143.28 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Alexion Pharmaceuticals, INC. | $120.81 | 2023-2025 | Strensiq |
| Cequr Corporation | $93.16 | 2023-2025 | Cequr Simplicity |
| Amneal Pharmaceuticals LLC | $91.16 | 2024-2025 | Unithroid |
| Beta Bionics, INC. | $67.45 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Insulet Corporation | $64.39 | 2024 | Omnipod |
| Sanofi-Aventis U.S. LLC | $56.01 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $43.05 | 2024-2025 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $42.81 | 2024-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $36.81 | 2024 | Farxiga |
| Averitas Pharma INC. | $32.21 | 2025 | Qutenza |
| Novartis Pharmaceuticals Corporation | $31.14 | 2024 | |
| Madrigal Pharmaceuticals | $19.01 | 2024 | Resmetirom |
| Neurocrine Biosciences, INC. | $18.12 | 2025 | |
| Abbvie INC. | $17.27 | 2023 | |
| Antares Pharma, INC. | $13.99 | 2024 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Tafflinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.